Why is lutetium-177 used in targeted radioisotope therapy?

The treatment combines lutetium-177 with a molecule designed to bind a marker on certain cancer cells. After the medicine is given, the targeting part helps it travel to and attach to cells with that marker. Lutetium-177 then releases beta radiation over a short range, which can damage the nearby cell. It also releases gamma radiation that may help the team detect where the medicine has travelled.

This approach works only when the tumour shows the relevant target and when your organs can handle the treatment. The treatment team may use scans, blood tests, and kidney or liver checks to decide whether it is appropriate.

Tell your team about kidney problems, liver disease, blood disorders, pregnancy, breastfeeding, and medicines or supplements. You may receive fluids or other medicines according to the protocol. Follow the radiation-safety instructions about contact with other people, hygiene, and handling body fluids; these instructions are temporary and individualised. Keep follow-up appointments so blood counts and organ function can be checked.

Contact your treatment team for fever, unusual bruising or bleeding, persistent nausea or vomiting, reduced urine, swelling, severe tiredness, or signs of infection. Seek urgent help for severe breathlessness, collapse, confusion, or uncontrolled bleeding. Do not wait for the next appointment if symptoms are sudden or severe.

Ask which marker the treatment targets, how it was confirmed, how kidney and blood health will be monitored, what safety precautions apply at home, and which symptoms need immediate contact.